A5015494717- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Head and Neck Cancer Studies
- Colorectal Cancer Treatments and Studies
- Intraperitoneal and Appendiceal Malignancies
- Myasthenia Gravis and Thymoma
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Esophageal Cancer Research and Treatment
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Healthcare Systems and Technology
- Immunotherapy and Immune Responses
- Diverticular Disease and Complications
- Gastric Cancer Management and Outcomes
- Patient-Provider Communication in Healthcare
- Palliative Care and End-of-Life Issues
- Telemedicine and Telehealth Implementation
- Global Cancer Incidence and Screening
University Hospital of North Norway
2016-2025
UiT The Arctic University of Norway
2007-2009
St Olav's University Hospital
2006
Haukeland University Hospital
2006
This randomised phase III study in advanced non-small cell lung cancer (NSCLC) patients was conducted to compare vinorelbine/carboplatin (VC) and gemcitabine/carboplatin (GC) regarding efficacy, health-related quality of life (HRQOL) toxicity. Chemonaive with NSCLC stage IIIB/IV WHO performance status 0–2 were eligible. No upper age limit defined. Patients received vinorelbine 25 mg m−2 or gemcitabine 1000 on days 1 8 carboplatin AUC4 day three courses 3-week cycles. HRQOL questionnaires...
The palliative role of chemoradiation in the treatment patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved. Patients not eligible for curative radiotherapy were randomised to receive either or chemotherapy alone. Four courses intravenous carboplatin on day 1 oral vinorelbin days 8 given 3-week intervals. arm also received fractionation 42 Gy/15, starting at second course. primary end point was overall survival;...
Chemoradiotherapy is standard treatment for limited stage (LS) small-cell lung cancer (SCLC). A majority of patients relapse and there a need better treatment. We investigated whether twice-daily thoracic radiotherapy (TRT) 60 Gy/40 fractions improve survival compared with the established schedule 45 Gy/30 fractions. Here we report final data long-term toxicity. Randomised, open-label, phase II trial. Eligible had PS 0-2, were ≥18 years, underwent FDG-PET/CT brain MRI staging randomised 1:1...
8011 Background: Durvalumab consolidation after chemoradiotherapy (CRT) has improved clinical outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC). Despite durvalumab treatment, a substantial proportion of relapse, while up to 20% achieve long-term survival without durvalumab. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection shown promise as tool for risk-adaptive and personalized treatment strategies resectable NSCLC but is still...
LBA8005 Background: A majority of patients with LS SCLC relapse after potentially curative CRT and better treatment is needed. Immunotherapy prolongs survival in extensive stage non-small cell lung cancer. We investigated whether atezolizumab (“atezo”) SCLC. Methods: Patients PS 0-2 non-progression (PD) platinum/etoposide chemotherapy concurrent twice-daily thoracic radiotherapy (TRT) 45 Gy/30 or 60 Gy/40 fractions were randomized 1:1 to observation atezo 1200 mg Q3W for 1 year, until PD...
Poor prognosis patients with bulky stage III locally advanced non-small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase trial concerning the effect of palliative CRT in inoperable poor patients, this analysis was performed to explore how tumor size influenced survival and health-related quality life (HRQOL).A total 188 recruited randomized clinical received four courses intravenous carboplatin day 1 oral vinorelbine 8, at 3-week intervals. The...
In a phase III trial of patients with unresectable, locally advanced, stage non-small-cell lung cancer (NSCLC) poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided significantly better outcome than chemotherapy alone, except among performance status (PS) 2 patients. the present subgroup analysis, we evaluated effect on aged ≥ 70 years (42% all included) compared < enrolled in trial.All received 4 courses intravenous carboplatin and oral vinorelbine. The experimental arm...
Introduction. Nearly 40% of patients with advanced NSCLC are in performance status (PS) 2. These have a shorter life expectancy than PS 0/1 and they underrepresented clinical trials. Data on how platinum-based combination chemotherapy affects Health Related Quality Life (HRQOL) 2 scarce the treatment this important group is controversial. Methods. A national multicenter phase III study platinum based to 432 included 123 To explore impact HRQOL, development HRQOL during first nine weeks were...
8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID 45 Gy/30 fractions the most recommended schedule. Trials report 5-year survival rates up to 36%, illustrating that some are cured but also need for better treatment. Many failures due relapses within fields, it has been proposed higher doses might improve local control consequently survival. However, high-dose once-daily (QD) 66-70 Gy do not prolong We investigated whether 60 Gy/40 was tolerable improved...
BackgroundPembrolizumab is a new drug approved in several countries for second-line therapy non-small cell lung cancer (NSCLC) being programmed death ligand (PD-L1) positive. This has high cost, and the cost-effectiveness ratio been debated.Patients methodsThe budget impact to Northern Norwegian Regional Health Authority trust of implementing pembrolizumab patients with PD-L1-positive NSCLC was calculated. A model developed employing data from Cancer Registry Norway, KEYNOTE-010 study, price...
The introduction of immune checkpoint inhibitors has transformed the treatment landscape metastatic non-small cell lung cancer. However, challenges remain to increase fraction patients achieving durable clinical responses these drugs and help monitor effect. In this phase II trial, we investigated toxicity, systemic circulating tumour DNA in (n = 21) with advanced non-small-cell cancer treated atezolizumab stereotactic body radiotherapy second or later line. We found combined be safe grade 3...
Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free (PFS) in advanced non-squamous non-small-cell lung cancer (NSCLC). However, few patients the control arms received at these trials, performance status (PS) two were ineligible of participants elderly. Thus, we designed this study comparing immediate switch-maintenance with chemotherapy.Methods: Patients stage IIIB/IV NSCLC, ≥18...
Introduction/Background: There has been a marked survival improvement for patients with non-small cell lung cancer. We describe the national trends in characteristics and survival, geographical differences diagnostic workup, treatment, small cancer.Materials Methods: Patients registered cancer at Cancer Registry of Norway 2002–2022 were included. Trends overall estimated all patients, limited stage cancer, undergoing surgery, by health region. Adjusting case-mix, multivariable Cox regression...
7033 Background: Carboplatin/vinorelbine (CV) and carboplatin/gemcitabine (CG) are novel 2-drug combinations in the treatment of NSCLC. In a randomized national multicenter phase III study stage IIIB IV patients (pts), we compared these regimens with respect to efficacy, toxicity quality life (QoL). Methods: Chemonaive pts histologically or cytologically proven NSCLC, ECOG performance status (PS) 0–2 were eligible. There was no upper age limit. Pts received vinorelbine 25 mg/m 2 gemcitabine...